Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells $1,063,173.54 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 10,582 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $100.47, for a total transaction of $1,063,173.54. Following the transaction, the insider directly owned 21,900 shares in the company, valued at $2,200,293. This trade represents a 32.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The shares were sold at an average price of $99.28, for a total transaction of $339,339.04.

Billiontoone Trading Up 1.5%

NASDAQ BLLN opened at $101.12 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The company has a market capitalization of $4.65 billion and a price-to-earnings ratio of 183.85. The company’s 50-day simple moving average is $88.03 and its two-hundred day simple moving average is $88.20. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $138.70.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $95.81 million. The company’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same period last year, the business posted ($0.39) EPS. Equities analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Guggenheim raised their target price on shares of Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. BTIG Research cut their target price on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Finally, Weiss Ratings cut shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 5th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Billiontoone has an average rating of “Moderate Buy” and an average target price of $125.29.

Institutional Trading of Billiontoone

A number of institutional investors have recently modified their holdings of the company. Rossby Financial LCC acquired a new stake in Billiontoone in the 4th quarter worth approximately $25,000. Wells Fargo & Company MN acquired a new stake in Billiontoone in the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC acquired a new stake in Billiontoone in the 4th quarter worth approximately $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Billiontoone in the 4th quarter worth approximately $82,000. Finally, Renaissance Capital LLC acquired a new stake in Billiontoone in the 4th quarter worth approximately $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.